Company Performance Metrics
Alan Watson: Executive Vice President & Chief Business OfficerPast Role: Elixir Pharmaceuticals, Executive Vice President & Chief Business Officer
Scott Waldman: Co-FounderPast Role: American College of Clinical Pharmacology, President
Targeted Diagnostics & Therapeutics, Inc. (TDT) has developed advanced technologies for use in the diagnosis and treatment of colorectal cancer and other gastrointestinal diseases. These technologies can provide physicians with new approaches for patient care. This website is intended to be a resource for patients, their families and
physicians.
TDT has emerged as a leader in the development of innovative molecular diagnostics and therapeutics that can improve the quality of life of patients with colorectal cancer and gastrointestinal malignancies.
Focused on innovative research and cutting edge technology, TDT has developed highly specific tests to detect colorectal cancer cells in lymph nodes from patients who have undergone surgical staging for colorectal cancer. The information derived from this test can assist physicians in making decisions about the administration of chemotherapy to improve disease-free survival.
A similar test has been developed for the detection of circulating colorectal cancer cells in blood. This determines that patients undergoing post-operative surveillance for recurrent colorectal cancer remain free of disease. Intensive research and development is being conducted on treating metastatic colorectal cancer with novel therapeutic agents specifically targeted only to those cancer cells.
